These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 31705387

  • 1. Teriparatide (rhPTH 1-34) treatment in the pediatric age: long-term efficacy and safety data in a cohort with genetic hypoparathyroidism.
    Tuli G, Buganza R, Tessaris D, Einaudi S, Matarazzo P, de Sanctis L.
    Endocrine; 2020 Feb; 67(2):457-465. PubMed ID: 31705387
    [Abstract] [Full Text] [Related]

  • 2. Teriparatide (rhPTH) treatment in children with syndromic hypoparathyroidism.
    Matarazzo P, Tuli G, Fiore L, Mussa A, Feyles F, Peiretti V, Lala R.
    J Pediatr Endocrinol Metab; 2014 Jan; 27(1-2):53-9. PubMed ID: 23945122
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study.
    Clarke BL, Kay Berg J, Fox J, Cyran JA, Lagast H.
    Clin Ther; 2014 May; 36(5):722-36. PubMed ID: 24802860
    [Abstract] [Full Text] [Related]

  • 4. Recombinant human parathyroid hormone (1-84) replacement therapy in a child with hypoparathyroidism.
    Laurer E, Grünberger J, Naidoo U, Lanzersdorfer R, Wimleitner M, Tischlinger K, Högler W.
    Bone; 2021 Mar; 144():115834. PubMed ID: 33359892
    [Abstract] [Full Text] [Related]

  • 5. Successful treatment of vitamin D unresponsive hypoparathyroidism with multipulse subcutaneous infusion of teriparatide.
    Puig-Domingo M, Díaz G, Nicolau J, Fernández C, Rueda S, Halperin I.
    Eur J Endocrinol; 2008 Nov; 159(5):653-7. PubMed ID: 18703565
    [Abstract] [Full Text] [Related]

  • 6. Drug safety evaluation of parathyroid hormone for hypocalcemia in patients with hypoparathyroidism.
    Marcucci G, Della Pepa G, Brandi ML.
    Expert Opin Drug Saf; 2017 May; 16(5):617-625. PubMed ID: 28332412
    [Abstract] [Full Text] [Related]

  • 7. Continuous Subcutaneous Recombinant Parathyroid Hormone (1-34) Infusion in the Management of Childhood Hypoparathyroidism Associated with Malabsorption.
    Saraff V, Rothenbuhler A, Högler W, Linglart A.
    Horm Res Paediatr; 2018 May; 89(4):271-277. PubMed ID: 28926829
    [Abstract] [Full Text] [Related]

  • 8. AN OPEN-LABEL EXTENSION STUDY OF PARATHYROID HORMONE RHPTH(1-84) IN ADULTS WITH HYPOPARATHYROIDISM.
    Lakatos P, Bajnok L, Lagast H, Valkusz Z.
    Endocr Pract; 2016 May; 22(5):523-32. PubMed ID: 26684150
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study.
    Mannstadt M, Clarke BL, Vokes T, Brandi ML, Ranganath L, Fraser WD, Lakatos P, Bajnok L, Garceau R, Mosekilde L, Lagast H, Shoback D, Bilezikian JP.
    Lancet Diabetes Endocrinol; 2013 Dec; 1(4):275-83. PubMed ID: 24622413
    [Abstract] [Full Text] [Related]

  • 10. Recombinant human parathyroid hormone (1-84) is effective in CASR-associated hypoparathyroidism.
    Hawkes CP, Shulman DI, Levine MA.
    Eur J Endocrinol; 2020 Dec; 183(6):K13-K21. PubMed ID: 33112267
    [Abstract] [Full Text] [Related]

  • 11. Chronic hypoparathyroidism and treatment with teriparatide.
    Marcucci G, Masi L, Cianferotti L, Giusti F, Fossi C, Parri S, Gronchi G, Brandi ML.
    Endocrine; 2021 Apr; 72(1):249-259. PubMed ID: 33538953
    [Abstract] [Full Text] [Related]

  • 12. Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study.
    Clarke BL, Vokes TJ, Bilezikian JP, Shoback DM, Lagast H, Mannstadt M.
    Endocrine; 2017 Jan; 55(1):273-282. PubMed ID: 27734257
    [Abstract] [Full Text] [Related]

  • 13. Continuous rhPTH (1-34) treatment in chronic hypoparathyroidism.
    Fuss CT, Burger-Stritt S, Horn S, Koschker AC, Frey K, Meyer A, Hahner S.
    Endocrinol Diabetes Metab Case Rep; 2020 May 29; 2020():. PubMed ID: 32478671
    [Abstract] [Full Text] [Related]

  • 14. Treatment of severe life threatening hypocalcemia with recombinant human teriparatide in patients with postoperative hypoparathyroidism - a case series.
    Andrysiak-Mamos E, Żochowska E, Kaźmierczyk-Puchalska A, Popow M, Kaczmarska-Turek D, Pachucki J, Bednarczuk T, Syrenicz A.
    Endokrynol Pol; 2016 May 29; 67(4):403-12. PubMed ID: 27387245
    [Abstract] [Full Text] [Related]

  • 15. The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics.
    Gittoes N, Rejnmark L, Ing SW, Brandi ML, Björnsdottir S, Hahner S, Hofbauer LC, Houillier P, Khan AA, Levine MA, Mannstadt M, Shoback DM, Vokes TJ, Zhang P, Marelli C, Germak J, Clarke BL.
    BMC Endocr Disord; 2021 Nov 20; 21(1):232. PubMed ID: 34801015
    [Abstract] [Full Text] [Related]

  • 16. Therapy of Hypoparathyroidism With rhPTH(1-84): A Prospective, 8-Year Investigation of Efficacy and Safety.
    Tay YD, Tabacco G, Cusano NE, Williams J, Omeragic B, Majeed R, Gomez Almonte M, Bilezikian JP, Rubin MR.
    J Clin Endocrinol Metab; 2019 Nov 01; 104(11):5601-5610. PubMed ID: 31310310
    [Abstract] [Full Text] [Related]

  • 17. Therapy of Hypoparathyroidism With PTH(1-84): A Prospective Six Year Investigation of Efficacy and Safety.
    Rubin MR, Cusano NE, Fan WW, Delgado Y, Zhang C, Costa AG, Cremers S, Dworakowski E, Bilezikian JP.
    J Clin Endocrinol Metab; 2016 Jul 01; 101(7):2742-50. PubMed ID: 27144931
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.